RT Journal Article
SR Electronic
T1 A novel strategy to express different antigens from one modified vaccinia Ankara vaccine vector
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 191924
DO 10.1101/191924
A1 K. B. Lauer
A1 E. A. McKenzie
A1 Y. Hall
A1 C.P.C. Gowda
A1 P. Klapper
A1 R. Borrow
A1 P.J. Vallely
A1 M. W. Carroll
A1 T. J. Blanchard
YR 2017
UL http://biorxiv.org/content/early/2017/09/21/191924.abstract
AB To enhance global control of encephalitis and hepatitis caused by rabies-(RABV), Japanese encephalitis-(JEV), hepatitis B-virus (HBV), and enterovirus 71 (EV71) novel immunisation strategies are needed. Therefore, a multipathogen modified Vaccinia Ankara vector, expressing antigens from the above pathogens, was constructed. Two recombinants, one carrying the EV71 and JEV pathogen sequence and one the RABV-HBV pathogen sequence were generated. To ensure similar expression of the antigens, a T7-promoter was linked to the expression cassettes of all pathogen sequences. Direct regulation of this promoter was achieved through co-infection with a second T7-polymerase expressing MVA. Protein expression using this co-infection model of expression was demonstrated in vitro. To investigate the co-infection model of antigen delivery in vivo, a murine immunogenicity study was performed using the MVA-RABV-HBV recombinant. Although, serum antibodies against MVA were induced in all mice, no serum antibodies against RABV or HBV could be detected.